Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €36.03 EUR
Change Today -0.08 / -0.22%
Volume 98.0K
GRF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Mexico
Continuous
Continuous
Frankfurt
Frankfurt
As of 5:21 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Vallès

Barcelona, 08174

Spain

Phone: 34 935 71 22 00

Fax: 34 935 71 02 67

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products. The company specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Its products and services are used by healthcare providers in approximately 100 countries to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions, and have a direct presence, through the operation of commercial subsidiaries, in 28 countries. Divisions The company organizes its business into four divisions, such as Bioscience, Diagnostic, Hospital and Raw Materials and Others. Bioscience The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products the company manufactures are IVIG (intravenous immunoglobulin), Factor VIII, alpha-1 proteinase inhibitor (A1PI) and albumin. The company also manufactures intramuscular (hyperimmune) immunoglobulins, antithrombin III (ATIII), Factor IX and plasma thromboplastin component. The company’s principal plasma derivative products are IVIG, A1PI, Factor VIII and albumin, each sold under various brand names. Gamunex IVIG was launched in the United States and Canada in 2003 as a premium ready-to-use liquid IVIG product. Gamunex IVIG is the only IVIG product approved for Chronic Inflammatory Demyelinating Polyneuropathy in the United States. Prolastin A1PI is the A1PI product in the United States, and in Europe, it is licensed in 15 countries. In Italy and Spain, the company distributes Prolastin directly. Additionally, Prolastin-C is the only licensed A1PI product in Canada, and the company is conducting clinical trials in Europe to obtain Prolastin-C approval there. Alphanate and Fahndi, the company’s Factor VIII/von Willebrand factor products, are used both for the treatment of hemophilia and von Willebrand disease. In addition, it offers its albumin product with reduced aluminum content, meeting European requirements and making its albumin product more attractive to biotechnology companies and genetic labs, as well as hospitals and physicians. The company produces intramuscular (hyperimmune) immunoglobulins, which are used for the treatment of tetanus, hepatitis B, and Rh factor complications during birth; Anbinex and Thrombate III, which are used in the prevention and treatment of thromboembolic complications; AlphaNine and Factor IX Grifols, which are used in the prevention and control of bleeding in patients with hemophilia B; and Niuliva and Igantibe, used after liver transplants to prevent hepatitis B reinfection of the graft. The company has 652 hemoderivative product licenses registered in 90 countries throughout the European Union, United States, Latin America, Asia and the rest of the world. Its significant government-issued licenses for plasma derivative products are Flebogamma/Flebogamma DIF/Gamunex/Gamunex-C Immunoglobulin; Fahndi/Alphanate/Koate Factor VIII; Human Albumin Grifols/Albutein/Plasbumin Albumin; and Prolastin/Trypsone A1PI. Flebogamma/Flebogamma DIF/Gamunex/Gamunex-C Immunoglobulin: The company has 122 licenses for the marketing and sale of one or more of these immunoglobulin products. Fahndi/Alphanate/Koate Factor VIII: The company has 99 licenses for the marketing and sale of one or more of these Factor VIII products. Human Albumin Grifols/Albutein/Plasbumin Albumin: The company has 198 licenses for the marketing and sale of albumin products in its various concentrations. Prolastin/Trypsone A1PI: The company has 25 licenses for the marketing and sale of 1 or both of these A1PI products. Pursuant to the Consent Order, the company has granted Kedrion the exclusive license to sell Koate-DVI in the United States. The company also provides virus photo-inactivation of transfusion plasma to hospitals and clinics in Spain. D

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRF:SM €36.03 EUR -0.08

GRF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $134.48 USD -4.85
Endo International PLC $73.48 USD -3.52
H Lundbeck A/S kr196.00 DKK -2.60
Hospira Inc $89.96 USD -0.01
UCB SA €69.11 EUR +2.48
View Industry Companies
 

Industry Analysis

GRF

Industry Average

Valuation GRF Industry Range
Price/Earnings 24.9x
Price/Sales 3.4x
Price/Book 4.1x
Price/Cash Flow 15.5x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.